Introduction
============

Gadolinium-based contrast agents are widely used as CE-MRI agents for diagnosing or monitoring disease progress. In each year, over 30 million doses of GBCAs are consumed worldwide, and more than 300 million doses have been administrated since their introduction ([@B17]). Clinically available GBCAs are all bonded by a ligand when they are used as an MRI contrast agent because free gadolinium is highly toxic ([@B53]). Until 2006, all GBCAs were considered extremely safe. In 2006, a report ([@B30]) stated that some GBCAs may lead to NSF in patients with renal failure. However, when performing careful evaluation of the renal glomerular filtration rate before CE-MRI, new NSF cases have not been reported. Since 2013, the safety of GBCAs has attracted broad attentions over the world. A research group from Japan reported ([@B23]) that signal intensity in the GP and DN on unenhanced T1 weighted imaging (T1WI) may be a result of the previous GBCAs administrations. This phenomenon leads to reconsideration of the safety of GBCAs. Following this report, many studies ([@B11]; [@B33]; [@B36]; [@B32]) focused on the potential risks of gadolinium retention in the human brain.

In this review, we summarize the current evidence on gadolinium deposition in the human and animal bodies, evaluate the effect of different types of GBCAs on the gadolinium deposition in brain, introduce the possible entrance or clearance mechanism of the gadolinium and potential side effects of gadolinium deposition in brain, and put forward some suggestions for further research.

The Physicochemical Properties of GBCAs
=======================================

Gadolinium is a paramagnetic material which can shorten the T1 relaxation time of living tissues. Based on the type of ligand and charge, the commercially available GBCAs can be classified into 4 different types ([@B14]): linear ionic, linear non-ionic, macrocyclic ionic, and macrocyclic non-ionic. Macrocyclic GBCAs form a rigid cage including a preorganized cavity for Gd^3+^ ion, while linear ligands form more flexible cages that wrap around the Gd^3+^ ion and are not fully closed. The differences in thermodynamic and kinetic stability of those ligands may be caused by their different chemical structures, whereby the non-ionic linear chelates are the least stable and the ionic macrocyclic chelates are the most stable ([@B10]). **Table [1](#T1){ref-type="table"}** gives the physicochemical properties of the commercially available GBCAs in current clinical practice.

###### 

Biochemical properties of gadolinium-based contrast agents currently approved for clinical use.

  Chemical structure          Trade name   Thermodynamic stability contrast   Conditional stability   Elimination pathway
  --------------------------- ------------ ---------------------------------- ----------------------- ----------------------
  **Linear**                                                                                          
  Nonionic                                                                                            
  Gadodiamide                 Omniscan     16.8                               14.9                    Renal
  Gadoversetamide             Optimark     16.6                               15                      Renal
  Ionic                                                                                               
  Godopentetate dimeglumine   Magnevist    22.1                               17.7                    Renal
  Gadobenate dimeglumine      Multihance   22.6                               18.4                    93%Renal; 3%Biliary
  Gadoxeticacid disodium      Primovist    23.5                               NA                      50%Renal; 50%Biliary
  Gadofosveset trisodium      Multihance   22                                 NA                      91%Renal; 9%Biliary
  **Macrocyclc**                                                                                      
  Nonionic                                                                                            
  Gadoteridol                 Prohance     22.8                               17.1                    Renal
  Gadobutrol                  Gadavist     21.8                               NA                      Renal
  Ionic                                                                                               
  Gadoterate meglumine        Dotarem      25.4                               19                      Renal

NA indicates not applicable.

The Association Between High Signal Intensity on Unenhanced T1WI and Previous GBCAs Administrations In Human
============================================================================================================

T1-hyperintensity in the human brain is not a rare phenomenon. Many diseases such as multiple sclerosis (MS), Wilson disease, post-radiation therapy, hepatic encephalopathy ([@B52]; [@B25], [@B26]; [@B54]) etc., can lead to T1-hypeyintensity in deep gray matter. In the past 4 years, the correlation between previous GBCAs administrations and T1-hyperintensity in the deep brain has become a hot topic. [@B23] firstly described the T1-hypeyintensity in GP and DN may be caused by the previously repeated linear chelates GBCAs administrations. In this study, 19 adult patients with brain tumors previously receiving at least 6 doses of linear GBCAs (gadopentetate dimeglumine or gadodiamide) and 16 patients only receiving at least 6 unenhanced MRI without the GBCAs administrations were included. After calculating the mean signal intensity of the DN, GP, pons, and thalamus on unenhanced T1WI, T1-hyperintensity in deep gray matter nuclei only occurred in patients who previously exposed to GBCAs. The hyperintensity of DN and GP on unenhanced T1WI was associated with the number of previous GBCAs administrations independent on patients' renal function. In the same year, Errante et al. ([@B11]) found T1 hyperintensity of the DN was common in patients with brain metastases who had undergone multiple gadolinium-enhanced brain MRI. In this study, 37 patients with brain metastases and 38 patients with MS underwent at least 2 consecutive CE-MRI examinations, and the results showed there were a linear relationship between T1 hyperintensity and the number of CE-MRI scans in patients both with brain metastases and MS. Since then, many studies demonstrated that repeated administrations of various types of linear GBCAs were associated with T1-hyperintensity in the brain ([@B65]; [@B45]; [@B27]; [@B69]). **Figure [1](#F1){ref-type="fig"}** shows a representative case with hyperintensity of the DN following repeated CE-MRI scans.

![A patient with optical nerve pilocytic astrocytoma who treated with 5400-cGy radiation therapy and underwent 25 times CE-MRI scans show hyperintensity of the DN on unenhanced T1WI. DN initially appears as slightly hyperintense **(A)**. During the follow-up studies performed at 5 **(B)** and 8 **(C)** years after the initial hyperintense appearance of the DN, the signal intensity of the DN become more obvious. Image courtesy of Dr. Mehmet Emin Adin, Russell H. Morgan Department of Radiology, Division of Neuroradiology, Johns Hopkins Medical Institutions, Baltimore, MD. Images and text reproduced from reference 1 with written permission from AJNR.](fnmol-11-00335-g001){#F1}

The same findings were also reported in pediatric patients. [@B50] described a pediatric patient with repeated GBCAs administrations, progressive hyperintensity on unenhanced T1WI involving the DN and GP was observed. Similar phenomenon was also reported by others ([@B36]; [@B13]; [@B18]; [@B49]). **Table [2](#T2){ref-type="table"}** presents the current evidences of gadolinium deposition in pediatrics and adult brain.

###### 

Association between CNS structures hyperintensity and GBCAs administration in human.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                  Groups                                                                                                                                   Contrast agent                                     MFS and sequence                                                                          Remarks
  ---------------------- ---------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------- ----------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Adult study**                                                                                                                                                                                                                                                                                              

  [@B23]                 19 patients underwent more than 6 CE-MRI examinations; 16 patients underwent more than 6 unenhanced examinations                         Gadopentetate-dimeglumine Gadodiamide              1.5T                                                                                      High SI in the DN and GP was associated with the number of previous CE-MRI examinations

  [@B11]                 38 patients with MS underwent more than 2 times CE-MRI scans; 37 patients with brain metastases underwent more than 2 CE-MRI scans       Gadodiamide                                        1.5T and 2-D TSE T1-weighted                                                              Increase signal intensity on unenhanced T1WI has a linear relationship with the CE-MRI in patients with MS and BM

  [@B65]                 50 patients underwent more than 5 CE-MRI                                                                                                 Gadobenate-dimeglumine                             1.5T T1-weighted spin echo 3.0T fast low-angle shot                                       The SI ratio in the DN was increased after serial gadobenate dimeglumine administrations

  [@B1]                  184 patients treated with brain irradiation underwent 2677 MRI studies                                                                   Almost exclusively Gadopentetate-dimeglumine       1.5 or 3.0T MPRAGE, Spin-echo sequence and T1WI FLAIR                                     Repeated CE-MRI examinations likely results in persistent hyperintensity in the DN on unenhanced T1WI

  [@B69]                 13 patients with more than 39 chelates GBCA administrations                                                                              Gadodiamide Gadopentetate-dimeglumine Gadobenate   1.5T or 3.0T 2D spin echo T1-weighted sequence 3D spoiled gradient-echo volume sequence   Increased SI on unenhanced T1WI was seen in the posterior thalamus, substantia nigra, red nucleus, cerebellar peduncle, colliculi, DN, and GP

  [@B45]                 18 patients with previous gadodiamide and current gadobenate dimeglumine exposed; 44 patients with only gadobenate dimeglumine exposed   Gadodiamide Gadobenate-dimeglumine                 1.5T fast spin echo T1-weighted images                                                    Compared to those patients without previously gadodiamide-exposed, the prior gadodiamide-exposed groups show greater T1 SI changed

  [@B27]                 9 patients received 1-8 times gadopentetate dimeglumine; 26 patients without prior GBCA exposure                                         Gadopentetate-dimeglumine                          1.5T mixed fast spin echo pulse sequence                                                  GBCA exposure patients show shorter T1 value compared with patients without prior GBCA exposure

  **Pediatrics study**                                                                                                                                                                                                                                                                                         

  [@B36]                 A pediatric patient who received 35 doses of linear GBCA during 12 years                                                                 Gadopentetate-dimeglumine                          1.5T T1-weighted turbo-spin-echo                                                          The DN, GP, and posterior thalamus showed visually evident increase in hyperintensity over the cause of repeated CE-MRI scans

  [@B50]                 A 13 years old girl with follow-up CE-MRI scans                                                                                          Gadopentetate-dimeglumine                          1.5T or 3.0T                                                                              With the increasing use of GBCAs, hyperintensity was noted within both the DN and GP bilaterally

  [@B49]                 16 patients underwent more than 5 consecutive CE-MRI scans                                                                               Gadopentetate-dimeglumine                          1.5T or 3.0T T1-weighted spin-echo\                                                       The number of prior GBCA doses is significantly correlated with progressive\
                                                                                                                                                                                                                     \                                                                                         T1-weighted DN hyperintensity
                                                                                                                                                                                                                     Sequence                                                                                  

  [@B18]                 21 patients received 5--37 times CE-MRI scans during their medical treatment; 21 controls of similar age without GBCA exposed            Gadopentetate-dimeglumine                          1.5T T1 weighted 2-D fast spin echo                                                       In all 21 patients with GBCA exposed, increased SI ratios were 18.6% ± 12.7% for the DN, and 12.4% ± 7.4% for the GP between the first and the most recent MRI scans

  [@B13]                 46 pediatrics patients underwent more than 3 times CE-MRI scans; 57 age-matched GBCA-naive control subjects                              Gadopentetate-dimeglumine                          1.5T T1-weighted spin-echo sequence T1-weighted 3-D MPRAGE sequence                       SI in the pediatric brain increases on unenhanced T1-weighted MRI with repeated exposure to linear GBCA
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MFS, Magnetic Field Strength; SI, Signal intensities, DN, Dentate nucleus; GP, Globus pallidus; CE-MRI, Contrast enhanced magnetic resonance imaging; MS, Multiple sclerosis; BM, Brain metastases; FLAIR, Fluid attenuated inversion recovery; MPRAGE, magnetization prepared rapid acquisition of gradient echo sequence.

Histological Analysis Confirmed Gadolinium Deposition in Human Brain
====================================================================

The association between previous GBCAs administrations and T1 hyperintensity in DN and GP has been confirmed via human brain autopsy studies and animal studies. [@B33] compared the gadolinium contents of 23 (10 in contrast group and 13 in control group) deceased patients' DN, pons, GP, and thalamus tissues by transmission electron microscopy, ICP-MS, and light microscopy. They found patients in the contrast group had 0.1--58.8 μg gadolinium per gram of tissue with a significant dose-dependent relationship, which was consistent with changes of signal intensity on unenhanced T1WI. It seemed the gadolinium could pass the BBB and deposit in the capillary endothelium and neural interstitium in the patients from contrast group who had relatively normal renal function when undergoing MR examination. [@B21] confirmed the gadolinium accumulation in the brain after analyzing brain samples of five subjects who received GBCAs (gadopentetate dimeglumine, gadodiamide, gadoteridol) and five subjects with no history of GBCA administrations by ICP-MS. They found the inner segment of the frontal lobe cortex, cerebellar white matter, GP, and frontal lobe white matter had the detectable level of gadolinium accumulation, while the DN and GP had the highest level of gadolinium deposition. [@B32] compared postmortem neuronal tissue samples from five patients with 4--18 times CE-MRI examinations by using gadodiamide as contrast agent. They found gadodiamide-exposed patients had 0.1--19.4 μg of gadolinium per gram of tissue, and gadolinium was accumulated in the neuronal interstitium and capillary endothelium, even in the cell nucleus. All the aforementioned studies only detected the gadolinium deposition in patients with linear GBCAs administrations. One study by [@B37] evaluated whether macrocyclic chelates GBCAs might deposit in human brain. In this study, tissue samples were acquired from 9 decedents undergoing autopsy who received CE-MRI examination using only single type of non-NSF related GBCAs, including gadoteridol (*n* = 5), gadobutrol (*n* = 2), gadobenate (*n* = 1), and gadoxetate (*n* = 1). They found gadolinium deposited in various brain areas including the caudate nucleus, putamen, cerebral white matter, and pons, with the highest levels in DN and GP for all patients. This finding indicated gadolinium deposition could be independent on gadolinium types. However, more evidences are needed to further confirm this finding via sensitive ICP-MS brain tissue analysis. **Table [3](#T3){ref-type="table"}** presents the currently available reports of gadolinium deposition in brain with histological evidences. However, changes of T1 signal intensity are non-specific and can appear in several other pathological conditions such as calcium, manganese, iron, lipid, and other substances ([@B16]), further examinations and careful analysis are needed to verify what is responsible for the T1 signal intensity change.

###### 

Autopsy studies in human or animal models.

                      Group                                                                                                                                                                                                              Contrast agent                                                                        Detection methods                                                                                                                                   Remarks
  ------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Human study**                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  [@B33]              13 patients with more than 4 GBCA administrations; 10 patients without GBCA exposed                                                                                                                                Gadodiamide                                                                           ICP-MS; Transmission electron microscopy; Light microscopy                                                                                          Gadolinium CNS structures deposition was associated with GBCA administrations and was independently with patients age, sex, renal function or interval between GBCAs exposed and death
  [@B21]              5 patients received linear GBCAs before death; 5 patients with no history of GBCAs exposed before death                                                                                                            Gadopentetate-dimeglumine Gadodiamide Gadoteridol                                     ICP-MS                                                                                                                                              Gadolinium was deposited in the brain even in subjects without severe renal dysfunction, the highest accumulation area was the DN and GP
  [@B37]              5 received gadoteridol; 2 received gadobutrol; 1 received gadobenate; 1 received gadoxetate; 9 patients without GBCAs exposed                                                                                      Gadoteridol Gadobutrol Gadobenate Gadoxetate                                          ICP-MS                                                                                                                                              Gadolinium was found with all agents in all brain areas sampled with highest levels in GP and DN
  [@B34]              5 patients underwent 4-18 times CE-MRI examinations; 10 patients with no history of GBCAs exposed                                                                                                                  Gadodiamide                                                                           ICP-MS; Transmission electron microscopy with energy-dispersive x-ray spectroscopy; Light microscopy                                                The patient DN, pons, GP and thalamus, contained 0.1--19.4 μg of gadolinium per gram of tissue in intracranial normality patients
  **Animal models**                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  [@B47]              7 rats with gadodiamide-treated; 7 rats with gadoterate; meglumine-treated 7 rats with hyperosmolar saline-treated                                                                                                 Gadodiamide Gadoterate meglumine                                                      ICP-MS                                                                                                                                              Repeated administration of the gadodiamide but not for the gadoterate meglumine were associated with T1-hyperintensity in the DN
  [@B48]              8 rats with gadobenate dimeglumine-exposed; 8 rats with gadopentetate dimeglumine-exposed; 8 rats with gadodiamide-exposed; 8 rats with gadoterate; meglumine-exposed 8 rats control group with saline injection   Gadobenate-dimeglumine Gadopentetate-dimeglumine Gadodiamide Gadoterate-dimeglumine   ICP-MS R1-mapping                                                                                                                                   Linear chelates GBCAs, gadodiamide, gadobenate dimeglumine, gadopentetate dimeglumine were associated with T1 hyperintensity in the DN along with gadolinium deposition in the cerebellum while gadoterate meglumine-exposed rats with no abnormal signal intensity observed
  [@B28]              10 rats received gadodiamide; 10 rats received gadopentetate dimeglumine; 10 rats received gadobutrol; 10 rats received gadoteridol; 10 rats received saline as control group                                      Gadodiamide Gadopentetate-dimeglumine Gadobutrol Gadoteridol                          ICP-MS; LA-ICP-MS; Scanning electron microscopy coupled to energy dispersive x-ray spectroscopy and transmission electron microscopy respectively   The administration of linear GBCAs was associated with significant high gadolinium concentration in the brain and skin compared to macrocyclic GBCA administration, however, no histopathological findings were detected in the rat's brain.
  [@B6]               8 pigs received gadobutrol and gadopentetate dimeglumine 5 received gadobutrol only                                                                                                                                Gadobutrol Gadopentetate-dimeglumine                                                  ICP-MS                                                                                                                                              Repeated gadobutrol exposure is not associated with gadolinium deposition in healthy pigs' brain, but additional a single dose gadopentetate dimeglumine is sufficient for gadolinium accumulation in the DN and GP

GBCA, Gadolinium-based contrast agent; ICP-MS, Inductively coupled plasma mass spectroscopy; LA-ICP-MS, laser ablation coupled with ICP-MS; CNS, Central nervous system; DN, Dentate nucleus; GP, Globus pallidus.

The Effect of Gbcas Types on the Gadolinium Deposition
======================================================

Although autopsy studies have shown all GBCAs can lead to gadolinium deposition in brain, most clinical studies indicated linear GBCAs had more detectable gadolinium deposition than macrocyclic GBCAs. [@B41] compared signal intensity ratios of the GP and the DN to other structures on unenhanced T1WI in patients with linear chelates or macrocyclic chelates GBCAs exposure. Their study included two groups of 50 patients who received at least six consecutive MRI examinations exclusively using either a macrocyclic GBCA (gadoterate meglumine) or a linear GBCA (gadopentetate dimeglumine). They found signal intensity increase in the DN and GP on unenhanced T1WI was caused by serial application of the linear GBCAs rather than macrocyclic GBCAs. [@B22] evaluated 73 patients who had previously exposed to GBCAs (23 patients received linear GBCAs, 36 patients received macrocyclic GBCAs, and 14 patients received both types of GBCAs) and 54 cases with no history of administrating any kind of gadolinium chelates. They found that T1-hyperintensity in the DN was related with previous use of linear GBCA (gadopentetate dimeglumine) rather than macrocyclic GBCA (gadoteridol). Gadoxetic acid, or gadoxetate disodium has been used as a liver-specific MRI contrast agent since its introduction in 2008, and there was no study showing possible brain gadolinium deposition after using gadoxetic acid. [@B19] compared 33 patients with more than 5 times of gadodiamide exposure (linear-nonionic) with 33 patients with more than 5 times of gadoxetic acid exposure (linear-ionic) and found T1-hyperintensity in the DN was related with previous gadodiamide administrations but not gadoxetic acid administrations. However, the administrated gadolinium dose in gadoxetic acid was only a quarter of that in gadodiamide, which might influence the results of this study.

Many animal studies also supported the viewpoint that linear GBCAs had more detectable gadolinium deposition in brain than macrocyclic GBCAs did ([@B20]; [@B47],[@B48]; [@B28]; [@B6]). For example, [@B47] compared the signal intensity of DCN and the DN in healthy rats after exposing to some linear and macrocyclic agents. They divided 21 rats into 3 groups: gadodiamide-treated group, gadoterate meglumine-treated group and hyperosmolar saline group. This study showed repeated use of gadodiamide (linear agent) in healthy rats was related with persistent and progressive T1-hyperintensity in the DCN and gadolinium deposition in cerebellum, while in the gadoterate meglumine (macrocyclic agent) -treated group, no effect was observed. [@B6] collected the cerebellum, DCN, cerebral cortex, and pons of 15 pigs after repeated intravenous injections of GBCAs. Of the 15 pigs, 8 received up to 48 doses of gadobutrol and gadopentetate dimeglumine, 5 received up to 29 doses of gadobutrol only, and 2 had no GBCA administrations. After analyzing the gadolinium concentration in the aforementioned brain areas by ICP-MS, they found gadobutrol exposure was not associated with gadolinium deposition in pig brain while even a single additional administration of gadopentetate dimeglumine was sufficient for gadolinium accumulation in the DN and GP.

Macrocyclic Chelates GBCAs and Gadolinium Deposition in Human Brain
===================================================================

Although many studies showed the linear GBCAs were associated with the gadolinium deposition in human brain, some studies indicated macrocyclic chelate GBCAs also lead to T1-hyperintensity in brain. [@B59] revealed an obvious signal intensity increase in both GP and DN on unenhanced T1WI in patients with RRMS following multiple gadobutrol administrations. They divided 58 patients into 3 groups (27, 96--98, and 118 weeks) based on the intervals of contrast administrations. Patients receiving contrast agents with 27 weeks interval showed the largest increase in GP-to-thalamus signal intensity ratio, while a decrease in the GP-to-thalamus signal intensity ratio was found in patients receiving contrast agents with intervals of 96--98 weeks. However, this study did not consider other confounding factors such as other causes or disease process resulting in T1 hyperintensity, previous use of other contrast agents, and disease activity itself ([@B52]; [@B3]). [@B5] reported two patients without any linear GBCA administrations before and received 37 and 44 doses of gadubutrol respectively, and they found visually appreciable enhancement of the DN on unenhanced T1WI, which showed a significant linear association with the number of macrocyclic GBCA injections. This finding should be further confirmed in larger and better controlled prospective studies. Based on current evidences, it suggests that both linear and macrocyclic GBCAs can cause gadolinium retention, despite the very different levels of total gadolinium exposure.

Similarly, the controversy about whether the macrocyclic chelates may induce hyperintensity in the specific brain structures in pediatrics also exists. Although many studies ([@B40]; [@B46]; [@B63]; [@B55]) reported that only the linear chelates were associated with T1-hyperintensity in the brain while the macrocyclic chelates were not responsible for this change, some researchers also found that the administration of some macrocyclic chelates (gadoterate meglumine) was associated with T1 signal intensity changes in children ([@B35]).

Gadolinium Deposition Beyond The Brain
======================================

Gadolinium-based contrast agents can not only deposit in the brain, but also in the skin, bone, liver, and other organs. [@B15] found that gadodiamide or gadoteridol could deposit in the bones in patients undergoing total hip arthroplasty through inductivity coupled plasma atomic emission spectroscopy. Many other researchers ([@B68]; [@B9]; [@B29]) confirmed this finding. There was a positive correlation between the dose of GBCAs administration and the gadolinium concentration measured in bone. It's worth mentioning that macrocyclic chelates (gadobutrol) could accumulate in the bone and retain for 5 years after one injection ([@B29]), and autopsy study ([@B37]) demonstrated gadolinium level in the bone was 23 times higher than in the brain, which suggest that bone may act as a long-term storage site for gadolinium in the body. [@B51] reported gadolinium accumulation in the skin of one patient with normal renal function after exposure to 61 cumulative doses of GBCAs. [@B31] reported liver gadolinium deposition occurred in pediatric patients with iron overload but normal hepatic and renal function following CE-MRI examinations.

Being similar as the results in humans, the rat models ([@B32]) showed significantly elevated levels of elemental gadolinium in hepatic, splenic, and renal tissues following administration of high doses of GBCAs, although no tissue injury was observed in these organs.

Potential Pathway of GBCAs Entering Into the Brain
==================================================

There are two barrier systems in human brain, the blood-CSF and the BBB barrier. In normal conditions, GBCAs can not penetrate the intact BBB ([@B66]), while various illness conditions may affect BBB integrity and function and allow the GBCAs enter into the brain. Previous studies showed that gadolinium could deposit in the brain without intracranial abnormality ([@B32]). [@B20] evaluated the infiltration and distribution of 5 commercial GBCAs (gadopentetate dimeglumine, gadobenate dimeglumine, gadodiamide, gadoterate meglumine, gadobutrol) into the CSF in healthy rats. This study demonstrated the above-mentioned 3 linear chelates can increase and persist the DN to pons signal intensity ratios during up to 24 days observation. A CSF signal enhancement on postcontrast fluid-attenuated inversion recovery images (FLAIR) was found for all GBCAs independent of their chemical structure. Thus, the GBCAs passing from the blood into CSF might represent an initial pathway of GBCA infiltration into the brain. Nevertheless, to date, the underlying mechanism of gadolinium distribution into the DN and the GP remains unclear and needs be further studied.

Clearance of Gadolinium from the Brain
======================================

Previous studies focused on the signal intensity changes on unenhanced T1WI MRI and the histological analysis on gadolinium deposition, however, few studies to date have been conducted to investigate whether those materials were cleared. The hyperintensity disappearance of the DN during follow-up was firstly described by [@B1]. After that, [@B57] measured the gadolinium deposition level in healthy rats in 1 and 20 weeks after administrating linear chelates gadodiamide with up to 20 repeated doses. One week after dosing, gadolinium was detected in the brain at 0.00019% of the injected dose, and 20 weeks later, this diminished by approximately 50% (0.00011% of the injected dose). This study demonstrated partial clearance of the agents occurred over 20 weeks, however, it remains to be further confirmed in humans. [@B4] conducted a retrospective study in 13 patients with previous more than 6 times gadopentetate dimeglumine (linear chelate GBCA) administrations then switching to gadobutrol (macrocyclic chelate GBCA) administrations. They found the developed DN--to-pons and DN--to--cerebellar peduncle signal intensity ratios decreased during mean follow-up time of 28 months after the last gadopentetate dimeglumine administration. The mechanism of the decreased signal intensity ratio was ascribed to the GBCAs washout hypotheses, chelators in the patient's diet or medications, or the mixture of discussed mechanisms. However, the interaction between signal intensity and repeated gadobutrol administrations during follow-up can be further studied ([@B2]). As for the washout hypothesis, some researchers ([@B57]) approved the findings while other studies ([@B33]; [@B48]) did not demonstrate. These inconsistent results indicated that if washout occurs, maybe it is in very low level because earlier observation demonstrated no washout while longer follow-up imaging showed washout sign ([@B43]).

Potential Impacts of GBCAs Administrations
==========================================

With repeated GBCAs administrations, gadolinium can deposit in brain and other organs even in patients with normal renal function. However, the clinical implication of the gadolinium deposition in the brain remains poorly understood.

Although some adverse effects of gadodiamide administration were reported, no strong evidences showed gadolinium deposition in the brain induced adverse clinical effects. [@B39] reported gadodiamide administration caused spurious hypocalcemia, especially in patients with renal insufficiency and at doses of 0.2 mmol/kg or higher. [@B7] did a survey about patients' self-described toxicity related to GBCAs administrations. In this study, the most common symptoms were bone/joint pain and head/neck symptoms including vision, headache and hearing change. The study had a long list of limitations such as selection bias and validity problems, but constituted the first depiction of symptoms, which may be associated with gadolinium toxicity. One study by [@B8] evaluated the toxic effects of single and cumulative doses of gadobenate dimeglumine in neonatal and juvenile rats after receiving either saline or gadobenate dimeglumine at doses of 0.6, 1.25, or 2.5 mmol/kg. The authors reported no effects of gadobenate dimeglumine on cognitive function, behavior or any other parameters of rats, even at the highest administrated cumulative dose (15 mmol/kg). Thus, they concluded gadolinium in juvenile rat brain receiving single or cumulative gadobenate dimeglumine injection was minimal and non-impactful.

Gadolinium can deposit in the DN and GP and the potentially damaged GP may induce Parkinsonian symptoms. [@B67] performed a population-based study to assess the relationship between parkinsonism and gadolinium exposure. In this study, 246 557 patients underwent at least one MRI examination during the study, there were 99 739 patients receiving at least one dose of gadolinium, and 2446 patients receiving 4 or more CE-MRI examinations. The results demonstrated the incident parkinsonism developed in 1.17% of gadolinium exposed patients and 1.16% of unexposed patients, and no significant association between parkinsonism and gadolinium exposure and parkinsonism was discovered. [@B38] performed a retrospective study about the clinical cerebellar syndrome caused by gadoterate administration in ten patients who had previously received more than 20 doses of gadoterate. During 91-month follow-up, neither appearance of a rising cerebellar syndrome nor newly appeared symptoms or signs suggesting cerebellar toxicity were reported by the clinician.

Potential Confounding Variables on Gadolinium Deposition in Brain
=================================================================

Renal Function
--------------

Due to the majority of GBCAs excretion through the kidney, the researchers firstly concerned about the impact of renal function on the gadolinium deposition. [@B21] analyzed brain tissues of 5 subjects and found out GBCAs accumulated in brain of subjects without severe renal dysfunction. Thus, even if the patient has normal renal function, GBCAs can still deposit in the human body. In patients with renal dysfunction, the condition of gadolinium accumulation in the body remains poorly understood. [@B24] found renal dysfunction increased short-term gadolinium deposition in the bone, liver, skin, spleen, and kidney but it did not impact long-term gadolinium deposition. [@B42] compared 13 patients on chronic hemodialysis who underwent 78 CE-MRI examinations with linear chelates GBCA (gadoversetamid) administrations with 13 patients with normal renal function, and they found the gadolinium accumulation rate in the brain after linear GBCA exposure may be affected by renal function. So, only in necessary conditions, GBCAs should be used and stabilized forms should be preferred.

Patients' Disease Condition
===========================

Multiple Sclerosis
------------------

Multiple sclerosis patients need undergo brain MRI examinations both during periods of relapse and remission (every few months) to evaluate disease activity. The DN T1 hyperintensity was observed in patients with multiple sclerosis ([@B52]; [@B3]). This T1 hyperintensity was attributed to clinical disability, lesion load and brain atrophy ([@B42]), but not GBCAs administrations. Therefore, multiple sclerosis patients have been excluded from most investigations studying brain GBCAs deposition. However, some studies about the influence of different types of GBCAs administrations on gadolinium deposition were conducted in patients with MS and came to different results. In these studies, some researchers ([@B59]) reported DN-to-pons signal intensity ratios increased after repeated macrocyclic GBCAs administrations, while other researchers ([@B56]; [@B58]) concluded that multiple doses macrocyclic chelates administrations were not related to brain signal intensity changes in multiple sclerosis patients.

It appears disease spectrum has been associated with gadolinium deposition in human. One study ([@B62]) compared the gadolinium deposition difference between NMOSD patients and multiple sclerosis patients, and they showed patients with multiple sclerosis were prone to gadolinium accumulation while NMOSD patients had less tendency. The authors believed the differences in disease pathology and structure of gadolinium might impact gadolinium deposition.

Brain Irradiation
=================

Radiation-related brain injury may lead to calcifications, which can present as high signal intensity on the T1WI ([@B60]). Therefore, patients who have experienced brain irradiation are usually excluded from the studies investigating the relation of hyperintensity signal changes with previous administration of gadolinium. [@B61] observed 144 pediatric patients with CE-MRI examinations, including 55 patients with primary brain tumors and whole-brain irradiation, 19 with primary brain tumors and chemotherapy only, 52 with primary brain tumors without any treatments, and 18 with neuroblastoma without brain metastatic disease. This study demonstrated that at fewer numbers of GBCAs administration (≤10 times), whole-brain irradiation seemed to play a greater role in increasing the T1 signal intensity on unenhanced T1WI than administered GBCAs, while at a higher number of GBCAs administration (≥20 times), GBCAs seemed to contribute more to the increased signal intensity.

Magnetic Field Strength, MRI Sequence and Interval Time Between Examinations
============================================================================

Although many gadolinium deposition studies have been published, one major limitation of these studies is the variability of the MR imaging protocols. One study showed magnetic field strength might affect the T1 signal intensity, however, magnetic field strength did not change the reader's final diagnosis in any of the cases ([@B1]). Pulse sequence may directly or indirectly affect the detectability of T1 hyperintensity in the brain. [@B44] evaluated the T1 hyperintensity using spin echo (SE) sequence and magnetization prepared rapid gradient echo (MPRAGE) sequence and the result showed the DN/MCP signal intensity ratios were significantly higher when using SE than MPRAGE sequence. Thus, the two sequences should not be used interchangeably, and the baseline and final signal intensity ratios should be assessed by the same sequence. They recommended MPRAGE sequence as a simple screening tool in clinical practice for assessing patients with multiple GBCA exposure because of its intrinsic higher gray--white matter contrast. The interval time between baseline and final MRI examination (range: 96--1905 days) did not influence the final observation between the two sequences.

Regulatory Statements
=====================

Since the first report of gadolinium deposition in brain, many official regulatory statements have been published to warn the safe use of GBCAs. In 2017, the International Society of Magnetic Resonance in Medicine (ISMRM) Safety Committee claimed that no direct evidences from human beings or animal studies demonstrated any harmful effects related to the gadolinium deposition in the brain. However, several recommendations for the use of GBCAs in clinics and research were provided by ISMRM. The main recommendations are as follows: (1) The ISMRM urges caution in the use of gadolinium-based contrast agents, and GBCAs should not be used when not necessary; (2) The clinical indication and pertinent information about GBCAs administrations should be documented in the patient's medical record; (3) When choosing a gadolinium-based contrast agent, many factors should be considered, including pharmacokinetics, efficacy, relaxivity, patient age, potential side effects (like allergic reactions), probability of the need for repeated examinations, and cost. Institutions should evaluate these factors and consider that some agents might be with a greater propensity for deposition than others ([@B17]).

In December 19, 2017, the US Food and Drug Administration (FDA) reviewed available data about the gadolinium retention from GBCAs as part of its role in monitoring the post-market safety of drugs. They recommended that health care professionals should evaluate the retention characteristics of each agent when using a GBCA in patients with higher risk, such as those who may require repeated GBCA MRI scans to monitor a chronic condition. The FDA also stated as "a class-wide warning about gadolinium retention in the labeling of GBCAs and a new medication guide that should be presented to patients in advance of receiving a GBCA" ([@B64]).

The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) confirmed ([@B12]) restrictions on using linear gadolinium agents from July 7, 2017, the PRAC recommended that the intravenous linear agents gadobenic acid and gadoxetic acid should only be used for liver scans when they meet an important diagnostic need. Additionally, gadopentetic acid should only be applied for joint scans because the gadolinium concentration in the formulation used for joint injections is very low. All other intravenous linear agents (gadoversetamide adopentetic acid, and gadodiamide) should be suspended in line with the PRAC's March 2017 recommendation. Another kind of gadolinium agent known as macrocyclic agents (gadoteric acid, gadobutrol, and gadoteridol) is more stable and has a lower tendency to release gadolinium than linear agents. These can continue to be applied in their current indications but at the lowest doses that enhance images sufficiently and only when unenhanced body scans are not appropriate.

Future Perspectives
===================

Although rapidly increasing number of published articles, the knowledge on gadolinium deposition in the brain and its clinical significance is still insufficient. And there exist many unsolved problems and further studies are needed. Firstly, whether the deposited gadolinium in the brain may result in any clinical consequences unreported during periods of study observation. Large prospective randomized controlled trial should be performed to clarify this important issue. Secondly, the mechanism of GBCA deposition in the brain remains unknown, and several related problems are still unsolved, including the initial pathway of gadolinium entering into the brain, the potential saturation and washout effects, and the exact molecular structure of residual gadolinium. Thirdly, the mechanism of disease itself affecting the gadolinium deposition in the brain is still unknown. Are some groups of patients prone to gadolinium deposition in brain? Future studies should focus on these unsolved problems and give valid evidences to the public.

Conclusion
==========

Recently studies have confirmed gadolinium accumulation in human brain following repeated gadolinium based contrast agent administrations, regardless of an intact BBB or normal renal function. Linear chelates GBCAs can result in more gadolinium deposition than macrocyclic chelates GBCAs. However, the impact of the retained gadolinium in the brain remains unknown, which needs large prospective studies to clarify in future. It is recommended to take caution when using macrocyclic chelates GBCAs and keep as low doses as possible for reducing gadolinium accumulation in brain.
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BBB

:   blood brain barrier

CE-MRI

:   Contrast enhanced magnetic resonance imaging

CSF

:   cerebrospinal fluid

DCN

:   deep cerebellar nuclei

DN

:   dentate nucleus

GBCAs

:   Gadolinium-based contrast agents

GP

:   globus pallidus

ICP-MS

:   inductively coupled plasma mass spectroscopy

NMOSD

:   neuromyelitis optica spectrum disorder

NSF

:   nephrogenic systemic fibrosis

RRMS

:   relapsing-remitting multiple sclerosis, T1WI, T1-weighted imaging.
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